Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume - Should You Buy?

Key Points

• Inventiva’s trading volume surged 166% to approximately 1.89 million shares, while the stock fell to $3.775 from its prior close of $3.86.
• Analyst sentiment is broadly positive: MarketBeat reports a consensus “Buy” rating and a $15.75 price target, including Guggenheim’s increase to $14.00, though Weiss Ratings maintains a “sell” rating.
• Institutional investors own 19.06% of the company, with several funds recently initiating or expanding positions. Inventiva’s lead drug candidate, lanifibranor, is in late-stage development for MASH, a liver disease with limited treatment options.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) saw an uptick in trading volume on Wednesday . Approximately 1,886,695 shares were traded during trading, an increase of 166% from the previous session's volume of 709,668 shares.The stock last traded at $3.7750 and had previously closed at $3.86.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Cantor Fitzgerald started coverage on shares of Inventiva in a research report on Friday, July 17th. They issued an "overweight" rating for the company. Piper Sandler restated an "overweight" rating on shares of Inventiva in a research report on Wednesday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Inventiva in a research note on Friday, July 17th. Finally, Guggenheim upped their price objective on Inventiva from $11.00 to $14.00 and gave the stock a "buy" rating in a report on Tuesday. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $15.75.

Inventiva Price Performance

The business's 50-day moving average is $4.56 and its 200 day moving average is $4.90.

Institutional Investors Weigh In On Inventiva

A number of hedge funds and other institutional investors have recently modified their holdings of IVA. Engineers Gate Manager LP raised its holdings in Inventiva by 155.5% during the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company's stock valued at $269,000 after buying an additional 43,280 shares during the last quarter. Persistent Asset Partners Ltd bought a new stake in Inventiva in the 4th quarter worth $603,000. Seven Fleet Capital Management LP bought a new stake in Inventiva in the 1st quarter worth $1,111,000. Eventide Asset Management LLC purchased a new position in shares of Inventiva in the fourth quarter valued at about $1,155,000. Finally, Simplify Asset Management Inc. purchased a new position in shares of Inventiva in the fourth quarter valued at about $1,570,000. Institutional investors own 19.06% of the company's stock.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva's lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.